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In attempts to determine the crystal structure of small
molecule–protein complexes, a common frustration is the
absence of ligand binding once the protein structure has been
solved. While the ﬁrst structure, even with no ligand bound
(apo), can be a cause for celebration, the solution of dozens of
apo structures can give an unwanted sense of de ´ja ` vu. Much
time and material is wasted on unsuccessful experiments,
which can have a serious impact on productivity and morale.
There are many reasons for the lack of observed binding in
crystals and this paper highlights some of these. Biophysical
methods may be used to conﬁrm and optimize solution
conditions to increase the success rate of crystallizing protein–
ligand complexes. As there are an overwhelming number of
biophysical methods available,some of the factorsthat need to
be considered when choosing the most appropriate technique
for a given system are discussed. Finally, a few illustrative
examples where biophysical methods have proven helpful in
real systems are given.
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1. Introduction
1.1. Why do we need to know about complexes?
Crystal structures of protein–small molecule complexes
often provide deeper insights into the structure and
mechanism of a protein than are revealed by an apo structure
alone. In some instances, nascent ligand pockets reveal them-
selves in the protein only when prompted to open up when an
appropriate ligand is bound (Scapin et al., 2003). These can
show unexpected opportunities in recognition or selectivity
that cannot be readily predicted by bioinformatics or com-
putational analysis. Intricacies of enzyme mechanism only
surmised and guessed at by detailed kinetic experiments can
be greatly facilitated by the ability to trap complexes along the
reaction pathway (Bitto et al., 2006). Whilst the site of ligand
binding is often known, sometimes only a crystal structure of
the liganded protein can truly conﬁrm the nature of the
interactions involved and the extent of the binding site. On
rare occasions, the unexpected can occur and ligands are
found in completely unpredicted allosteric sites, which would
have been difﬁcult to unravel except by the ability to crys-
tallize the complex (Horn & Shoichet, 2004). Of course, for
structure-based drug design, iterative complex crystal struc-
ture determination is vital to guide the progress of synthetic
chemistry efforts (Williams et al., 2005). For the crystallo-
graphic data to have impact, complex structures must keep
pace with the chemistry within a project. Progression of a
crystallographic system from one that is able to produce single
‘one-off’ structures to one that is robust enough to cope with
the demands of generating complex structures ‘on demand’ is
still one of the most challenging aspects of structure-baseddrug discovery. Even for established systems, the failure rate
in obtaining X-ray complexes can be signiﬁcant and highly
compound-dependent. The scale of the problem and the
wasted resources cannot be underestimated. For example, it
has been stated by one major pharmaceutical company that
65% of their desired complex data sets turned out to be
unliganded when the structures were ﬁnally solved. No doubt
some systems demonstrated more success than others, but in
our experience all crystallographic systems will generate a
proportion of failed complexes within their lifetime.
1.2. Why can there be problems in generating structures of
complexes?
When crystallography is used as a screening tool to identify
ligands that bind to a protein (Hartshorn et al., 2005), it is
expected that many apo structures will be observed, as there
will be a signiﬁcant proportion of inactive molecules tested.
However, when attempts are made to obtain a small mole-
cule–protein structure, there is usually prior knowledge and
expectation that the chosen ligand will bind. Sometimes, this
expectation is unwarranted and the compound does not and
has never bound to the protein in any form. Whilst this may
seem a trivial reason for failure, it is unfortunately more
common than one might hope and is worth bearing in mind
before exploring other avenues. For ligands arising from a
screening campaign, it is important to remember that all
techniques have limitations and artefacts, and it may be wise
to reconﬁrm the initial observation, maybe using an ortho-
gonal method to avoid continued frustration (Chung et al.,
submitted work). For example, a primary screen that monitors
changes in ﬂuorescence polarization on displacement of a
ﬂuorescent compound from the active site of a protein may be
followed by an orthogonal activity assay that measures the
inhibition of substrate turnover by a colorimetric readout.
Ideally, the ﬂuorescence and colorimetric emission and exci-
tation wavelengths should not overlap. Activity in only one of
the assays may highlight molecules with spectral properties
that interfere with the assay readout or molecules that interact
directly with the active-site probe (e.g. ﬂuorescent compound
or substrate) rather than the protein itself. Alternatively, the
secondary assay may be one that monitors ligand binding
directly without the need for a probe molecule, such as surface
plasmon resonance (SPR), nuclear magnetic resonance
(NMR) or isothermal titration calorimetry (ITC).
The most probable common sources of failure to generate a
small molecule–protein complex relate to differences between
the assay conditions originally used to identify the interaction
and those necessary to generate high concentrations of
homogeneous complex for crystallization trials. Issues can
arise from the protein itself and the conditions used for
complex formation. Often, the crystallographic construct is
not identical to the assay protein. Sometimes, it is truncated to
what is believed to be the critical and most compact form, with
sites of potential heterogeneity, such as phosophorylation or
other post-translational modiﬁcations, mutated away. Unfor-
tunately, these changes may signiﬁcantly alter the binding
afﬁnity of the ligand, possibly to the extent that the ligand has
little residual afﬁnity for the crystallographic construct,
making it difﬁcult to generate a complex during the cocrys-
tallization or soaking procedures. Success may also be inﬂu-
enced by the practical details of how complexation is
attempted. For example, the way in which the ligand is added
to the protein, the length of the incubation period, buffer
conditions and the presence of other components, such as
detergents and cofactors, all inﬂuence the outcome.
Once liganded, a protein complex may have markedly
different solubility and self-association properties from the
apo protein. The original apo crystallization conditions may
no longer favour the formation of a crystalline lattice for the
complex and re-screening for new crystallization conditions
may be required. For weaker complexes, there can be a
substantial proportion of free protein within the crystallization
drop and it is possible that the unbound protein crystallizes
more readily than the complex, resulting in only unliganded
data sets being collected. This is less likely to occur for high-
afﬁnity ligands where little unliganded protein is present and
the favourable lattice energy for apo crystal formation must be
sufﬁciently high to compensate for complex dissociation.
Finding factors that drive the solution equilibrium towards
complex formation and are compatible with crystallization will
clearly enhance the pursuit of X-ray complexes. Unfortu-
nately, while many factors can be important, those that are
critical will be system-dependent. It is vital to identify the key
attributes of the protein and of the conditions that are most
likely to lead to successful complex formation on a case-by-
case basis. This paper therefore details how biophysical
methods may be used to address two fundamental questions:
(i) does a compound bind to the crystallographic protein? and
(ii) if so, under what conditions?
1.3. Which method to use?
There are a myriad of ways of monitoring ligand binding
and no single ‘right’ method. For any system, it will be possible
to apply a range of methods. Therefore, what are the consid-
erations one should think about when trying to make a
choice?
(i) Consider the system, the attributes of the system, the
handling issues and limitations. For example, the availability of
ligand and protein reagents, the robustness of the protein and
whether there are any intrinsic probes that may be useful. For
cytochrome P450s and other haem-containing proteins, UV
methods are well established and may offer a site-speciﬁc and
easy way to check complex formation.
(ii) Consider the information that is critical to progress the
experiments. For example, whilst quantitative afﬁnity
measurements may be a bonus, it may be sufﬁcient to merely
differentiate between ligands that are able to form complexes
and those that are not.
(iii) Consider the technique or maybe combination of
techniques that allow access to this critical information,
preferably with least effort, least ambiguity and with the type
of reagents that are available.
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method, so it is very important to match the limitations of the
protein system to the strengths and failings of the techniques.
Failure to do this can compromise the quality of the infor-
mation or lead to signiﬁcantly more effort than necessary to
obtain a deﬁnitive result. For example, if it is critical to
understand the afﬁnity of a number of ligands as a function of
pH (e.g. if crystals only form at low pH) and to know their
binding stoichiometry of the interaction (e.g. to help interpret
the crystallographic electron density), then it may be sensible
to consider methods that allow the generation of all these data
in a straightforward fashion. SPR and ITC are two methods
that can determine afﬁnity and stoichiometry simultaneously,
provided care is taken in determining the active protein
concentration. In some instances, these direct methods may
have advantages over activity assays, which may have a
restricted operational pH range, and displacement assays,
where a probe and its afﬁnity proﬁle over the pH range is
required.
Many biophysical methods can measure ligand binding at
low concentrations, with ultimate sensitivity being achieved by
single-molecule techniques. None of these are discussed in this
article, as it is impossible to cover the vast array of methods
able to monitor protein–ligand interactions in a single review.
Instead, the focus is to introduce four readily available tech-
niques and to highlight how they may be successfully applied
to guide crystallization attempts of protein–ligand complexes.
Three of these, isothermal titration calorimetry (ITC), nuclear
magnetic resonance (NMR) and dynamic light scattering
(DLS), can study proteins at or close to crystallographic
concentrations in a nondestructive manner. They have the
advantage of being able to look at the very same sample that
goes on to crystallization trials. The fourth method measures
shifts in thermal stability on ligand binding. This is normally
run at lower protein concentrations and is a destructive
technique. However, it is included because it has several
unique attributes.
An understanding of the requirements for complex forma-
tion may also help in soaking experiments, although additional
complications such as ligand solubility, the kinetics of binding
within a protein crystal, the fragility of crystals on soaking etc.
are also factors which are not covered in the context of this
paper.
2. Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) is probably the gold
standard of direct binding methods and involves measuring
the heat produced (exothermic) or taken in (endothermic)
during a reaction, such as the binding of a ligand to a protein
(O’Brien et al., 2001). The experiment takes place in an
isothermal titration calorimeter at constant temperature.
Typically, the ligand solution is repetitively injected in small
aliquots from an automatic syringe into a thermally isolated
stirred cell containing the protein (Fig. 1). The ﬁrst injection of
ligand produces the largest amount of protein–ligand complex
and therefore the largest heat change. On subsequent injec-
tions there are fewer unoccupied sites on the protein, so less
additional complex is formed and the heat change decreases.
Ultimately, all the protein sites are saturated and at the end of
the titration no further heat change arising from complexation
is observed.
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Figure 1
(a) Schematic diagram of an isothermal titration calorimetry instrument, consisting of a sample cell that contains one binding component, an automated
syringe that contains the other binding partner and a reference cell. (b) Differences between the sample-cell and reference-cell temperatures induced by
binding are initially translated to the power needed to bring the two samples back to the same temperature, before conversion to a binding enthalpy in
molar terms.In theory, it is possible to obtain from a single experiment
very precise estimates of the association and dissociation
constants (Ka and Kd), the stoichiometry of the interaction (n)
and the reaction enthalpy (H). Thus, the entropy change for
the binding can also be calculated via the following thermo-
dynamic relationships
G ¼  RT lnKa; ð1aÞ
G ¼ H   TS; ð1bÞ
Kd ¼ 1=Ka: ð1cÞ
In practice, to accurately and simultaneously determine all
these parameters (G, H, S, n and Ka) requires the initial
molar concentration of protein in the cell to be deﬁned by
10<ðKa  ½ protein Þ<100: ð2Þ
Therefore, for a binding event with Ka =1 0
5 M (Kd =1 0mM),
the optimal cell concentration should lie between 100 and
1000 mM. For a protein of Mr 50 000 with a Microcal ITC
instrument, which requires a minimum of 1.8 ml of solution to
ﬁll the cell, this equates to between 9 and 90 mg of protein for
each experiment. For ligands with higher afﬁnities, the protein
concentration can be dramatically reduced, but the minimal
concentration required then becomes dependent on the
magnitude of H. If the concentration becomes too low, then
the signal will become dominated by background contribu-
tions, such as those arising from ligand dilution and buffer
mismatch. A typical ITC experiment is likely to use greater
than  0.5–1 mg of protein regardless of the afﬁnity. Running
‘an ideal’ ITC experiment requires not
only good experimental design and
practice, but also some prior knowledge
of H and Kd, which means an initial
ITC experiment is often necessary to
estimate these values.
It is possible to envisage how the
simplicity and high information content
of the ITC experiment, combined with
its nondestructive nature, could be
incorporated into a cocrystallization
protocol where conﬁrmation of
complexation is required but protein
supply is limited. This is illustrated in
Fig. 2. Fig. 2(a) shows a ‘typical’
cocrystallization protocol where ligand
is added to the protein and the mixture
pre-incubated on ice for anything from
minutes to hours. Sometimes this is
performed at modest protein concen-
trations so that a concentration step is
required and sometimes at higher
concentrations. Regardless of the
precise details of the process, there are
often no checks to conﬁrm the success
or completeness of complex formation
for small ligands. If this ﬁnal ‘complex’
solution fails to generate crystals, it is
unclear whether this is a complexation
issue or a crystallization problem.
Alternatively, if only apo crystals are
formed, then it is unclear whether any
complex was ever present. Fig. 2(b)
shows how the ITC experiment can be
used as a more controlled way of
combining the protein and ligand, with
the additional advantage of generating
thermodynamic and binding informa-
tion ‘for free’. After a successful ITC
experiment, where ligand has been
injected into a cell containing protein,
the ﬁnal cell contents contain a
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Figure 2
(a) Flowchart of a typical protocol to produce a solution of a complex, where protein and ligand are
simply combined. (b) The simple combination of protein and ligand may be replaced by an ITC,
where additional data on the binding stoichiometry, enthalpy and afﬁnity can be gathered en route
to crystallization trials.
Figure 3
(a) The aromatic portion of the spectrum of the collagen-like peptide Ac-(GPO)2GFO-
GER(GPO)3-NH2 is shown at 277, 288 and 298 K. The far left peak highlighted in this spectrum
corresponds to the triple-helical form of the peptide and increases in abundance at lower
temperatures. (b) Spectra of the same aromatic region at 298 K at varying protein:ligand (P:L)
ratios is shown. The preferential broadening of the triple-helical form on protein addition is
highlighted by the arrow.conﬁrmed saturated protein complex ready to be concentrated
for cocrystallization trials.
This has been used for a number of nonphosphorylated
kinase domains and for domains from a transcriptional regu-
lator with no measureable enzyme activity. A typical starting
point may use 10–20 mM protein within the cell and 100–
200 mM ligand injections at 277 K. In the case of poorly
soluble ligands, the titration can be reversed, with 10–20 mM
ligand placed into the cell and the protein contained within the
syringe. In this conﬁguration additional ligand must be added
to the cell contents after the ITC experiment to ensure that the
protein is saturated prior to concentration for crystallization
trials.
There are situations where this simple ‘ITC’ modiﬁcation to
the complexation protocol is not appropriate or informative.
For example, if the ligand is very sparingly soluble in aqueous
solution then an aqueous titration is not possible even if the
titration format is reversed. It is also not applicable where the
binding event is entirely entropically driven. However, this
method of recycling the ﬁnal ITC contents for crystallization
has provided an efﬁcient use of protein in several instances,
especially when the crystallographic constructs lack an alter-
native assay. The unique thermodynamic deconvolution of the
binding energy into its enthalpy and entropy contributions by
ITC should also be appreciated.
3. Nuclear magnetic resonance
NMR measures the resonance characteristics of magnetically
active nuclei with nuclear spin >1/2, such as naturally abun-
dant
1H and
19F or less abundant isotopes such as
15N and
13C
if the sample has been suitably enriched. It is a versatile and
information-rich technique which can be tailored to empha-
size the most informative NMR attribute for any particular
purpose. Consequently, there are a huge range of experiments
available. For example, combining experiments that highlight
molecular bond connectivities with those that give through-
space interactions can allow de novo three-dimensional
structures to be determined (Wishart, 2005; Nietlispach et al.,
2004). Here, discussions are restricted to experiments
designed for monitoring ligand binding (Guenther et al., 2004;
Peng et al., 2004).
It is useful to divide these NMR methods into two distinct
categories, ligand-based methods and protein-based methods,
as these have different properties.
3.1. Ligand-based NMR methods
Ligand-based methods, such as STD (Krishnan, 2005) and
waterLOGSY (Dalvit et al., 2001), scrutinize only the ligand
signals as a function of protein binding. Firstly, the position, or
chemical shift, of the resonances can change. The direction
and magnitude of the change depend on differences in the
ligand’s chemical environment between the bound and free
states and have been used to differentiate between several
postulated binding modes. Secondly, the shape of the signals
may change on binding, indicating that the NMR relaxation
properties of the ligand have been altered. A common
observation is peak broadening, as illustrated in the next
example.
One difﬁculty in using ligand resonances is spotting them
amongst potentially thousands of protein resonances. One
solution is to use NMR-active nuclei present in the ligand but
absent in the protein, such as
31Por
19F. Another solution is to
have a large excess of ligand over protein and then monitor
changes in ligand parameters as a function of sub-stoichio-
metric protein additions. For the excess ligand signals to
contain information about the bound state, the ligand-
exchange rate needs to be rapid compared with the chemical
shift difference between the bound and free signals. Typically,
this means modest (micromolar) to low-afﬁnity (millimolar)
interactions are best suited to this method.
Many biologically interesting protein–ligand interactions do
not have a simple 1:1 stoichiometry and ﬁnding appropriate
conditions to generate a complicated multicomponent com-
plex can be immensely challenging. When one component is in
an oligomeric equilibrium with oligomerization constants
comparable to crystallographic concentrations, the situation
becomes even more complex.
The synthetic collagen-like peptide Ac-(GPO)2GFO-
GER(GPO)3-NH2 (Emsley et al., 2004) is a useful tool for
exploring protein–collagen interactions as the peptide is able
to self-associate into the triple-helical structure typical of
collagen. This peptide has a single aromatic phenylalanine
residue, so the large number of signals in the aromatic region
of the NMR spectrum of this peptide indicates the presence of
several species in solution (Fig. 3a). The concentration (not
shown) and temperature-dependence (Fig. 3a) of these NMR
signals suggest that these species correspond to different
oligomeric states of the peptide in dynamic and reversible
equilibrium, the triple-helical form being more stable and
abundant at lower temperatures.
When a sub-stoichiometric amount (0.1:1) of a collagen-
binding domain from an integrin is added to the peptide at
298 K, selective broadening of the triple-helical resonances
are observed, indicating that the protein preferentially inter-
acts with this oligomer (Fig. 3b). No changes in the other
resonances are seen, an observation that is consistent with a
relatively weak interaction that competes with the oligomeric
equilibrium but is unable to signiﬁcantly perturb it under these
conditions.
Generating a homogeneous 1:1 protein:triple-helical
collagen peptide complex for crystallization may therefore be
difﬁcult. However, for any given protein:collagen concentra-
tion, lowering the temperature is likely to be beneﬁcal, as the
NMR results show that this increases the proportion of the
triple-helical form of the peptide in solution. This suggestion
was borne out in crystallization trials, where extensive
screening produced complex crystals only at temperatures
<283 K and these crystals were found to be highly tempera-
ture-sensitive.
This example illustrates how the high molecular interpret-
ability of NMR spectra (e.g. peaks corresponding to individual
atoms in molecules) and richness of information can give
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tous technique, able to work with as little as 5 ml of sample in a
nondestructive manner, it is one of the most versatile tools
available for biophysical analysis in a crystallographic context.
One major disadvantage of ligand-based experiments is that
no information can be inferred about the site of interaction
and speciﬁc and nonspeciﬁc interactions cannot be differ-
entiated. To ensure that a ligand binds in the desired site, an
additional experiment must be performed where the desired
site is made unavailable for binding. This may be achieved by
using a competitor for the active site or by using a mutant
protein no longer competent to bind ligand. Site-speciﬁc
information can also be gained using spin-labelled ligands
(Jahnke et al., 2000; Jahnke, 2002). Another way is to use
protein-based NMR experiments, where a binding site may be
determined without prior knowledge or tool compounds in
favourable circumstances.
3.2. Protein-based NMR methods
Protein-based NMR experiments concentrate on changes in
the protein spectrum upon ligand binding. As proteins have a
much larger number of atoms than their ligand counterparts,
many protein-based experiments focus on signals from a
selected subset of these atoms. To make the information even
clearer, these signals are often dispersed into two or more
dimensions to give multidimensional plots, as shown schema-
tically in Fig. 4.
Frequently, proteins enriched in rarer NMR nuclei are used
to increase the sensitivity and range of chemical subsets
accessible.
15N enrichment is the most popular and cost-
effective option and subsequent discussions will be limited to
use of the ubiquitous two-dimensional
1H–
15N correlation
spectrum shown schematically in Fig. 4(a). In this spectrum
each peak corresponds to a directly connected proton–
nitrogen pair, such as the NH of an amide, which means that
every residue in the protein backbone, except for proline,
gives rise to a peak in this spectrum. Provided there are no
global changes in structure upon ligand binding, the addition
of a ligand will cause only a subset of peaks proximal to the
binding site to be perturbed in a
1H–
15N spectrum, as illu-
strated in Fig. 4(b). This enables binding to be monitored and
the site of binding to be identiﬁed.
The power of this experiment lies with the easy access to
residue-resolved information and the fact that at crystallo-
graphic concentrations this spectrum can be acquired in a
matter of minutes with the sample returned intact. The HSQC
spectrum also contains peaks arising from side-chain N–H
pairs from residues such as asparagine, glutamine etc.,s o
sometimes it is possible to gain information about the inter-
actions made by these side chains.
Unlike ligand-based experiments, the
1H–
15N correlation
experiment can monitor interactions with a wide range of
afﬁnities (nanomolar to millimolar) without the need to alter
the experimental conditions. For fragment-based drug-
discovery approaches that attempt to start from weak but
chemically attractive molecules, conﬁrmation of binding and
the likelihood of speciﬁcity (i.e. site of binding) is easily
achieved using this experiment and may be a critical ﬁlter for
compound progression. In some systems, NMR may be ideal
for use as the initial screen to identify these chemical starting
points (Shuker et al., 1996; Jhoti, 2005).
SH2 domains are commonly found in intracellular proteins.
Their role is to sense the phosphorylation of speciﬁc tyrosine
residues within their partner proteins. They often lie at control
points in intracellular pathways and the ability to differentiate
between tyrosine and phosphotyrosine (pY) is critical to their
role in regulation.
Inhibitors of this regulation event that act by binding to the
SH2 domain require a suitable pY mimetic, which is probably
anionic. Ideally, these mimetics need to make good hydrogen-
bonding interactions in the pY pocket and yet have a low
enough charge to allow the inhibitor to enter cells and reach
the required site of action. One way such mimetics have been
identiﬁed is to directly screen small acid mimetics, with good
potential permeability properties, for their ability to bind at
the pY pocket. These mimetics can then be elaborated into
larger compounds to give the required potency and selectivity
(Lesuisse et al., 2002).
Despite the critical nature of the phosphotyrosine residue,
an isolated pY moiety only has an afﬁnity of the order of
millimolar for the SH2 domain. Successful mimetics have
similar potencies, making it challenging to identify and
conﬁrm the site of action of these fragments. A multitude of
biophysical methods have been successfully used to screen pY
mimetics. These include competition assays using pY peptides
and ﬂuorescence (Cousins-Wasti et al., 1996), radioactive
detection methods, SPR (Mandine et al., 2001) and noncova-
lent MS (Bligh et al., 2003). All these techniques have been
able to detect the binding of low-afﬁnity compounds to SH2
domains. However, they do not allow the site of action to be
precisely localized to the pY-binding pocket, as pY itself
cannot be used as a probe owing to its low intrinsic afﬁnity.
Crystallography of the pY mimetics would conﬁrm binding
at this site, but the problems associated with obtaining
liganded crystal structures are ampliﬁed when very weak
ligands are used and success rates can be very low. The HSQC
experiment can help both to focus efforts prior to crystal-
lization trials and to demonstrate speciﬁcity even in the
absence of successful liganded structures. This demonstration
can provide the conﬁdence needed to begin chemical efforts to
make inhibitors with greater potency that may be more
successful in subsequent crystallization attempts.
This was indeed the case for our discovery of the urazole
moiety as a novel phosphotryosine mimetic. Fragment-based
screening using a variety of biophysical methods [e.g. non-
covalent mass spectroscopy (Bligh et al., 2003), ﬂuorescence
polarization, scintillation proximity assay and NMR] on the
Src SH2 domain identiﬁed a number of urazole-containing
fragments which competed with phosphotyrosine peptide
binding with afﬁnities in the 1–5 mM range. These fragments
satisﬁed many of the criteria required for an ideal pY mimetic,
so there was great interest in understanding their binding
mode. Their potency was so low that all crystallographic
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However,
1H–
15N NMR conﬁrmed that all the urazole
moieties bound within the pY pocket. This provided the
evidence needed to make a modiﬁed recognition peptide with
the phosphate group replaced by the urazole heterocycle. This
had greater potency (30 mM) and the cocrystal structure of Src
SH2 with this urazole peptide was successful. An overlay of
the original pYEEI peptide complex with this variant (Fig. 5)
clearly demonstrates the phosphate mimicry of this fragment
within the pY pocket (Charifson et al., 1997; Chung, in
preparation).
4. Dynamic light scattering
Most sizing methods do not have the
resolution able to differentiate between
a protein and ligand-bound protein and
so are not generically useful for moni-
toring small-molecule binding. Nonco-
valent mass spectroscopy (Bolbach,
2005; Benesch & Robinson, 2006) is an
exception, but tends to be a rather
specialist activity needing considerable
effort to ensure a representative result.
For systems where ligand binding
induces protein oligomerization or gross
conformational changes, however,
monitoring these signiﬁcant size/shape
changes can be a convenient surrogate
for monitoring the ligand binding
directly.
For cocrystallization trials, DLS
(Brown, 1993; Schmitz, 1990) is a
particularly attractive option, as it
enables data to be gathered on the same
solutions as used for crystallization without dilution. This
removes any concerns regarding batch-to-batch variations and
the need to extrapolate between concentrations. The latter
consideration is especially important in multi-component
oligomeric systems, as the governing equilibria and kinetic
parameters are often unknown, causing any concentration
extrapolation to be unreliable.
Analytical ultracentrifugation (AUC) may also be used for
such studies and is preferable if very detailed characterization
of the oligomerization phenomenon is required (Gilbert,
2005). However, DLS is a technique available in many crys-
tallography laboratories and often provides rapid and conve-
nient access to sufﬁcient information to guide crystallization
experiments.
Dynamic light scattering monitors changes in the intensity
of scattered light from a sample as a function of time. These
ﬂuctuations are caused by the Brownian motion of the
molecules within a solution and can be correlated to the
particles’ diffusion coefﬁcient and size via the Stokes–Enstein
equation. It has been suggested that samples that are mono-
dispersed by DLS (that is, uniform and consisting of only one
particle size) are more likely to crystallize (Ferre-D’Amare &
Burley, 1997; Winzor, 2003). As protein samples go on to
experience a diverse range of conditions that may change their
behaviour during crystallization screening, this criteria is
rarely used to abandon crystallization trials (Stura et al., 2002),
but may be useful as a way of monitoring improvements in
protein behaviour (Jancarik et al., 2004).
A common obstacle to forming protein–small molecule
complexes is the limited solubility of the ligands. At equili-
brium, for the simple 1:1 interaction between a protein P and
ligand L described by
P þ Laq  !PL; ð3Þ
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Figure 5
Overlay of the crystal structures of the Src SH2 domain with acetylated
pYEEI peptide (PDB code 1a1b; in yellow) and the urazole derivative of
the YEEI peptide (in green; Chung et al., in preparation). The extensive
hydrogen-bonding interactions made by the urazole are shown by dotted
green lines. The excellent phosphate mimicry of the urazole heterocycle
within this recognition pocket is evident.
Figure 4
(a) The bottom panel shows a schematic representation of a two-dimensional
1H–
15N correlation
spectrum. Peaks in this spectrum can be assigned toamide NH pairs inthe protein backbone.(b)O n
addition of a ligand, NH pairs close to the binding molecule will be selectively perturbed, allowing
the binding site to be localized.the degree of complexation is dictated by the equilibrium
association constant Ka,
Ka ¼½ PL =½P ½Laq ; ð4Þ
where [P] is the free protein concentration, [Laq] the free
ligand concentration in solution and [PL] is the complex
concentration. For sparingly soluble ligands, this is compli-
cated by the fact that the free ligand concentration [Laq]
cannot exceed its solubility limit. It takes a limiting value of
[Lsat] regardless of the amount of excess ligand that is often
added, as this excess is precipitated as solid. In this case, the
concentration of complex achievable is determined by the
maximum solubility of the ligand [Lsat] and Ka. For a protein–
ligand solution where excess ligand (e.g. as solid) is present, as
described by
Ls  !P þ Lsat  !PL; ð5Þ
the free ligand concentration is equal to its saturation value,
i.e. [Laq]=[ L sat], and (4) becomes
K
 
a½Lsat ¼½ PL =½P : ð6Þ
This means that the ratio of complex to free protein is equal to
the product of the afﬁnity constant multiplied by the saturated
ligand concentration and is no longer dependent on the
protein concentration. For a compound with a solubility nine
times its dissociation constant ([Lsat]=9 Kd =9 / Ka), a 90%
complex solution will be generated regardless of the protein
concentration. In contrast, for a compound with a solubility
comparable to its dissociation constant ([Lsat]=1 / Kd = Ka),
only a 50% complex solution will be possible.
Whilst the practicalities of how the ligand is added to the
protein can have no bearing on the ﬁnal equilibrium complex
concentration, they can have a dramatic effect on the rate that
the equilibrium is attained and it is useful to have tools to
check this progress, as the next example illustrates.
DLS experiments were carried out on a protein known to
dimerize upon ligand binding, where a large number of
cocrystallizations had been attempted resulting in apo struc-
tures. Ligands for this system were identiﬁed in an assay using
the intact transmembrane oligomeric receptor. However, for
crystallographic studies only the excised extracellular ligand-
binding domain was used. There was thus no convenient assay
to conﬁrm ligand binding and no biological interest in the
crystallographic domain beyond its use to provide the mole-
cular details of the interactions.
For this system, DLS provided rapid answers to a number of
questions. Firstly, DLS was used at low protein concentrations
in the 0.3–1 mg ml
 1 range to conﬁrm that active ligands were
able to enhance protein dimerization and by implication bind
to the truncated protein. Moreover, the level of enhancement
paralleled the potency ranking of the compounds in the intact
receptor assay, providing conﬁdence that the crystallographic
protein would provide biologically relevant information.
Secondly, DLS was used to study the level of protein
dimerization of samples destined for crystallization trials in
order to try and improve the success rate of complex struc-
tures. A number of buffer parameters such as salt concentra-
tion and pH were explored, but the most critical determinant
in this system was the manner in which the ligand and protein
were combined. Initially, crystallization samples had been
produced by incubating protein at  10 mg ml
 1 with a vast
excess of solid compound in order to avoid the use of DMSO,
which was thought to be detrimental to cocrystallization. DLS
of a sample incubated overnight with a low-solubility
compound showed that the solution stayed monomeric after
this treatment; in fact, the protein remained monomeric even
after several days incubation at 277 K. In contrast, when
added as a concentrated DMSO solution (100 mM), the same
compound instantaneously induced complete protein dimer-
ization, even when only a modest ligand excess was present.
Clearly, in this simplistic case the kinetics of compound
dissolution was the rate-limiting step and was primarily
responsible for the lack of success. An efﬁcient way of forming
and checking complexes was therefore to add excess
compound from a concentrated DMSO stock with no need for
pre-incubation and to use this solution for cocrystallization
trials. If necessary, this same solution could be spun down and
used in the DLS to conﬁrm the complexation. In this case the
original DMSO sensitivity of the crystallization could be
overcome, but when this is not possible dialysis of the ﬁnal
complex or use of a more tolerated solvent may be necessary.
The important factor was being able to identify the key
limitation.
5. Thermal stability enhancements on ligand binding
The ability of ligand binding to enhance protein stability is a
well recognized phenomenon. The degree of stabilization can
be systematically probed by observing the increased resistance
of a protein to chemically or physically denaturing conditions,
such as urea or temperature. Many methods are able to
monitor the extent of denaturation, e.g. speciﬁc enzyme
activity, NMR, circular dichroism (CD) and, most recently,
extrinsic ﬂuorescence using a probe that binds selectively to
unfolded protein (e.g. Thermoﬂuor; Cummings et al., 2006;
Koblish et al., 2006).
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Figure 6
An idealized plot of the ﬂuorescence changes that occur during the
thermal denaturation of two proteins when a ﬂuorescent dye such as ANS
or Sypro Orange is used. The left curve shows the trace from a protein
that denatures with Tm = 318 K; the right curve shows one with
Tm = 333 K.Dyes such as ANS and Sypro Orange show enhanced
ﬂuorescence when bound to hydrophobic patches on proteins.
Protein denaturation tends to expose more of these areas, so
the observed ﬂuorescence increases during the transition from
native to denatured states. Fig. 6 shows the idealized transition
curves of two samples with different thermal stability, where
the melting temperature Tm is deﬁned by the mid-point of the
denaturation curves. Fluorescence intensity can easily be
measured in a plate-based format and this method of visual-
izing the temperature stability allows many samples to be
quickly characterized with relatively small amounts of mate-
rial, typically 20-–50 mlo f 0.1 mg ml
 1 protein (Vedadi et al.,
2006; Ericsson et al., 2006).
Proteins with very low thermal stability (<293 K) may
highlight a cause for concern; however, beyond this the
absolute value of Tm does not provide any information about
how likely a protein is to crystallize. Many factors that govern
the ability to form ordered crystals are independent of those
that determine Tm; there is no reason why a protein with a
lower Tm should not crystallize more readily than one with
higher Tm. The utility of Tm lies in its application in a
comparative context, where changes in Tm can identify those
factors that have the greatest inﬂuence on protein behaviour,
at least from a stability perspective.
There are numerous examples of proteins that do not
crystallize unless a ligand is present. In some instances, the
mere presence of a ligand is not truly sufﬁcient and high
diffraction quality requires high ligand potencies. This is the
situation for the ligand-binding domain (LBD) of many
nuclear receptors (NR), where the use of CD-detected Tm
experiments are well established (Watkins et al., 2003). One
advantage of using CD over a dye-based method is the ability
to interpret the CD spectrum in terms of the secondary and
tertiary structural elements within the protein, thus providing
a higher information-content assay.
Nuclear receptors are involved in transcriptional regulation.
Ligand binding can result in activation, deactivation or
modulation of biological activity depending on the confor-
mational change induced upon complexation and its effect on
the subsequent recruitment of partner proteins. In such a
complex system, NR ligands are often identiﬁed within assays
that maintain signiﬁcant biological context. These assays do
use the isolated LBD used for crystallographic studies and Tm
measurements provide a generic way of triaging compounds
for direct LBD interactors, regardless of their site of binding
or the conformational changes elicited. Binders should
enhance the protein stability, so
Tm ¼ TmðligandÞ TmðapoÞ>0:
Unfortunately, the afﬁnity of a ligand cannot be simply
determined from the saturation value of Tm (Matulis et al.,
2005). However,it may be possible to use the variation of Tm
as a function of the ligand concentration to extract an afﬁnity
constant. For a given protein, there is a tendency for Tm to
increase with potency.
When faced with a selection of many ligands for cocrys-
tallization trials, one way of prioritizing ligands may be to
proﬁle them using a ﬂuorescence thermal denaturation, Tm,
experiment. Those that produce no enhanced protein stability
do not interact strongly with the protein, at least under the
chosen conditions, so may be comparatively more difﬁcult to
cocrystallize than those that show strong enhancement or
binding. Those that produce large stability shifts are strong
binders and may be more ideal initial starting points. For some
systems both weak and strong binders will result in successful
X-ray complexes, while for others only the most potent inhi-
bitors can be observed. This again highlights why Tm cannot
be used in an absolute fashion, because the absolute
requirements for success are system-dependent.
When highly potent ligands known to bind to the crystal-
lographic protein repeatedly fail to produce complex struc-
tures, the effect of the extraordinary contents of the
crystallization solution are often questioned. Most biophysical
methods ﬁnd that the presence of high precipitant concen-
trations (e.g. salts, PEGs) interferes with binding measure-
ments. However,we have found that the ﬂuorescence Tm assay
is remarkably tolerant of a wide variety of conditions. It is
therefore possible to systematically probe the effect of every
component of the crystallization solution, e.g. pH, salt etc.t o
pinpoint the factor that has the greatest effect on the protein
stability and, by inference, complex formation. It is important
to remember that a suitable control must be run for each
experiment. For example, to ﬁnd out whether 1 M NH4SO4
has an effect on ligand binding, the appropriate reference Tm
must be from the apo protein also in 1 M NH4SO4, so only the
presence and absence of ligand distinguishes the two samples.
This is because the solution conditions themselves can affect
the intrinsic stability of a protein.
In the past, Tm measurements have been used to identify
stabilizing conditions for protein storage, often using differ-
ential scanning calorimetry (DSC). The thermal denaturation
experiment may be used in the same way to scan a variety of
buffer conditions to optimize protein handling and storage.
These conditions could include the effect of solubilizing
detergents. It maybe less appropriate to use Tm as a parameter
to choose additives designed to effect crystal growth, as factors
that modulate the growth habit may have little effect on the
intrinsic stability of the protein.
Whilst in principle a generic tool, there are instances where
the denaturation method fails. The denaturation process
cannot be visualized for all proteins. Some proteins precipitate
before dye binding occurs. Others do not fully unfold on
thermal denaturation and no signiﬁcant increase in dye
binding takes place (e.g. for some disulﬁde-bonded proteins).
More fundamentally, there are rare but documented examples
of nonspeciﬁc binding resulting in protein stabilization and
speciﬁc binding giving rise to unexpected destabilization as
measured by Tm (Horn & Shoichet, 2004). These caveats are
especially pertinent for low-afﬁnity ligands, where relatively
large compound concentrations may produce signiﬁcant
nonspeciﬁc effects similar to those seen with additives such as
arginine, glycerol etc. If only large Tm (>3 K) at low ligand
concentrations (<100 mM) are considered, the dangers of mis-
interpreting nonspeciﬁc interactions are reduced.
research papers
70 Chung   Obtaining liganded crystal structures Acta Cryst. (2007). D63, 62–716. Summary
Biophysical methods are an armoury of tools that can be
fashioned to provide key guiding information to enhance the
success of cocrystallization experiments. This review has
highlighted a few examples of their application in the focused
pursuit of crystal structures of protein–ligand complexes. Even
within this narrow arena, their use often provides unexpected
insights into the nature of the complexes formed. In our
attempts to gain a better understanding of the biological and
physical world, these tools provide unique information that is
unobtainable from and complementary to that provided by a
molecular structure.
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